树突状细胞相关胶质母细胞瘤免疫治疗研究进展  

Progress in immunotherapy of dendritic cell-related glioblastoma

作　　者：马晓良 梅敬威 徐佳鸣 MA Xiaoliang;MEI Jingwei;XU Jiaming(Department of Internal Medicine,Hangzhou First People's Hospital Jiande Branch(Jiande City Second People's Hospital),Jiande 311600,China;Department of Internal Medicine,The Second Affiliated Hospital of Bengbu Medical College;The Second Affiliated Hospital of Zhejiang University School of Medicine)

机构地区：[1]杭州市第一人民医院建德分院[建德市第二人民医院]肿瘤内科,浙江建德311600 [2]蚌埠医学院第二附属医院肿瘤内科 [3]浙江大学医学院附属第二医院神经外科

出　　处：《沈阳医学院学报》2022年第4期427-431,共5页Journal of Shenyang Medical College

摘　　要：中枢神经系统胶质母细胞瘤是最常见的原发性脑肿瘤类型,经手术治疗、放疗及化疗等综合治疗后,其生存期仍然很短。近年来,癌症免疫治疗方法在治疗实体肿瘤中取得巨大成功,关于树突状细胞疫苗的使用已引起广大研究者的兴趣,然而基于树突状细胞疫苗在胶质母细胞瘤治疗中的应用尚不普遍。本文就树突状细胞疫苗的免疫治疗在胶质母细胞瘤中的研究进展进行综述。Glioblastoma is the most common type of primary brain tumor in central nervous system.After surgery,radiotherapy and chemotherapy,its survival period is still very short.In recent years,cancer immunotherapy has achieved great success in the treatment of solid tumors.The use of dendritic cell vaccines has aroused the interest of many researchers.However,the application of dendritic cell vaccines in the treatment of glioblastoma is not universal.This article reviews the research progress of immunotherapy of dendritic cell vaccines in glioblastoma.

关 键 词：胶质母细胞瘤 树突状细胞疫苗 免疫治疗 

分 类 号：R739.41[医药卫生—肿瘤]